SCF-Skp2/Cks1 E3 ligase inhibitors (New York University School of Medicine/Baylor College of Medicine/University of Connecticul health center/Evotec/AptaChem Consulting/Cepter Biopartners)

N/A

Report date: 2025/03/20 20:00:06

NME

Base Information

Drug NameSCF-Skp2/Cks1 E3 ligase inhibitors (New York University School of Medicine/Baylor College of Medicine/University of Connecticul health center/Evotec/AptaChem Consulting/Cepter Biopartners)

Drug Alias NameN/A

ClassificationSmall molecules > Heterocyclic drugs

Mechanisms of ActionUbiquitin-protein ligases inhibitors

TargetsUbiquitin-protein ligases

Therapy Area/IndicationsCarcinoma, Endometrioid

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited StatesUnited Kingdom

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesEvotec (UK) Ltd

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesCepter Biopartners AptaChem Consulting Evotec (UK) Ltd +[6]

Active IndicationsN/A

Inactive IndicationsCarcinoma, Endometrioid

Other Information

ATC CodeN/A